RetiVue DR, a point and shoot, non-mydriatic, widefield retinal camera for diabetic eye screening

RetiVue DR，一款用于糖尿病眼部筛查的傻瓜式、免散瞳、宽视场视网膜相机

• 批准号: 9409553
• 负责人: Ming Lai
• 金额: $ 92.67万
• 依托单位: RETIVUE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-30 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9409553
• 关键词: Adult; Affect; Age; Agreement; Algorithms; Americas; Anatomy; Animals; Area; Blindness; Caring; Clinic; Clinical; Clinical Trials; Collaborations; Color; Complex; Custom; Darkness; Detection; Devices; Diabetes Mellitus; Diabetic Retinopathy; Diagnostic; Diagnostic Imaging; Direct Costs; Disease; Early Diagnosis; Electronics; Ensure; Evaluation; Eye; Eye Movements; Eye diseases; Fundus; Generations; Gold; Human; Image; Imagery; Imaging technology; Iris; Knowledge; Lasers; Learning; Legal patent; Light; Lighting; Masks; Medical; Methods; Modeling; Movement; Ophthalmic examination and evaluation; Optics; Patients; Peripheral; Phase; Photography; Physicians; Positioning Attribute; Predictive Value; Primary Health Care; Procedures; Process; Pupil; Resolution; Retina; Retinal; Sensitivity and Specificity; Specificity; Speed; Surface; System; TNFRSF10B gene; Technology; Time; Training; Ultraviolet Rays; Validation; Visible Radiation; Vision; base; compliance behavior; cost; cost effective; design; detector; diabetic; diabetic patient; image processing; improved; innovation; laptop; lens; novel; point of care; prevent; prototype; sample fixation; screening; seal; sensor; success

Project Summary Over the past two decades, diabetic retinopathy (DR) has become the leading cause of adult blindness in the US, affecting 40% of all diabetic patients and resulting in $500 million a year in direct medical costs. Vision loss due to DR is largely preventable and can be reduced by up to 90% with appropriate eye screening. However, in the US, less than 50% of diabetic patients receive a recommended yearly eye exam due to many factors that include lack of access to eye care professionals. Distributed tele-ophthalmic screening thru primary care clinics can potentially provide all diabetic patients cost- effective, yearly evaluations to detect DR and prevent vision loss. However, gold-standard sensitive detection of DR using standard retinal photography is complex and cumbersome process requiring up to 7 images per eye. This screening process cannot for all practical purposes be achieved without having highly trained ophthalmic photographers. RetiVue proposes to develop the RetiVue DR in collaboration with Olympus, to create the first handheld, non- mydriatic, 160 field of view, widefield DR screening camera. It will allow single photo capture of an area up to ten times greater than conventional fundus cameras, allowing sensitive detection of DR at its earliest time points. Full integration of RetiVue and Olympus hardware will enable the most advanced and highest image quality handheld retina camera on the market. Use of automated alignment, auto laser focus, and auto image capture will allow complex imaging of the retina to be performed simply by positioning the iris, requiring no user knowledge of retinal anatomy. We have established clinical proof of concept with our patented technology, but require several additional innovations in optical design, automated image recognition, and retinal image processing to enable a commercial device. We will for this proposal optimize our alignment system and laser based focusing system for widefield imaging, allowing automated alignment and focus to image the retina before eye movement occurs. We will develop a new method of widefield, non-mydriatic peripheral retinal imaging using multiple LED slit-beam projectors to allow rapid, segmental, sequential image capture of 90°, 120°, and 160° FOV on diabetic patients. Finally, we will create the most advanced retinal image processing algorithms to remove Purkinje haze which prevents conventional cameras from imaging beyond 45° FOV and enable seamless stitching of segmental peripheral retina images into a single widefield image.

项目摘要 在过去的二十年中，糖尿病性视网膜病（DR）已成为成人失明的主要原因 美国，影响所有糖尿病患者的40％，每年的直接医疗费用为5亿美元。想象 由于DR造成的损失在很大程度上是可以预防的，并且可以通过适当的眼睛筛查最多减少90％。 但是，在美国，只有不到50％的糖尿病患者因许多 包括缺乏眼部护理专业人员的因素。 通过初级保健诊所的分布式恐怖筛查可以潜在地为所有糖尿病患者提供成本 - 有效的年度评估，以检测DR并防止视力丧失。但是，金标准敏感检测 使用标准视网膜摄影的DR是复杂且繁琐的过程，最多需要7张图像 眼睛。如果没有经过高温训练，就无法实现此筛查过程 眼科摄影师。 与Olympus合作开发entivue dr的提案，以创建第一个手持式，非 - MyDriatic，160视野，广场博士筛选摄像头。它将允许将一个区域捕获到 比传统的眼底摄像机大十倍，可在最早的时间敏感地检测DR 点。视网膜和奥林巴斯硬件的完整整合将启用最先进和最高的图像 市场上优质的手持视网膜相机。使用自动对齐，自动激光焦点和自动图像 捕获将使视网膜的复杂成像仅通过放置虹膜来执行，而不需要用户 视网膜解剖学知识。 我们已经通过我们的专利技术建立了临床概念证明，但需要其他几个 光学设计，自动图像识别和视网膜图像处理的创新 商业设备。我们将为此建议优化我们的对齐系统和基于激光的聚焦系统 用于广场成像，允许自动对准并聚焦在眼睛移动之前图像视网膜 发生。我们将开发一种使用多个的广阔田，非毛利率外围视网膜成像的新方法 LED狭缝束投影仪可在90°，120°和160°FOV上快速，节段，顺序的图像捕获 糖尿病患者。最后，我们将创建最先进的残差图像处理算法以删除 Purkinje Haze防止常规摄像机成像超过45°FOV并启用无缝 将节段的周围视网膜图像缝合到单个广场图像中。